相关实验视频

Updated: Jun 5, 2025

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

塞马格卢提德通过HSDL2减少高脂肪引起的心肌细胞损伤

Lin Yang^1,2, Xiaoyu Pan², Zhenyu Pan³

¹Department of Internal Medicine, Hebei North University, Zhangjiakou, Hebei, People's Republic of China.

Drug design, development and therapy

|December 5, 2024

概括

塞马格卢提德通过减少氧化应激和降低氧类固醇脱酶类蛋白2 (HSDL2) 的降低调节来缓解肥胖引起的心脏损伤. 这表明了管理高脂肪饮食相关心脏损伤的新疗法途径.

科学领域:

心脏病学心脏病学
代谢障碍代谢障碍代谢障碍
分子生物学分子生物学

背景情况:

肥胖会引发炎症和氧化应激,损害心脏细胞 (心肌细胞).
水氧类固醇脱酶样蛋白2 (HSDL2) 影响脂质代谢.
塞马格卢提德对葡萄糖和体重管理有影响.

研究的目的:

研究肥胖引起的心肌损伤中的氧化应激和HSDL2表达.
阐明与肥胖有关的心脏损伤的机制.
通过HSDL2调制评估塞马格卢提德对心肌损伤的影响.

主要方法:

已建立的小鼠肥胖模型与塞马格卢提德治疗.
使用了用棕酸处理的心肌细胞与HSDL2淘汰.
测量了炎症和氧化应激标志物,并评估了HSDL2和自水平.

主要成果:

塞马格卢提德的干预减少了与肥胖相关的氧化应激.
在肥胖的人群中,赛马格卢提德下调HSDL2表达.
HSDL2淘汰赛减弱的棕酸诱导的氧化应激和自.

结论:

塞马格卢提德可以通过调节HSDL2.2,防止高脂肪饮食引起的心肌细胞损伤.
这些发现提供了对心脏损伤的分子机制的见解.
确定肥胖相关心脏病的潜在新临床标.

关键词:

在HSDL2中使用.这是一种炎症炎症炎症炎症.肥胖肥胖肥胖肥胖肥胖肥胖肥胖肥胖氧化应激是一种氧化应激.塞马格卢提德 (semaglutide) 是一种可怕的药物.

更多相关视频

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

相关概念视频

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...